Table 5.
Clinical outcomes of COVID-19 patients treated with immunosuppressive drugs
| Variables | Total (n = 199) | Discharged (n = 122) | Expired (n = 77) | Tocilizumab single doses (n = 102) | Tocilizumab double doses (n = 48) | Tocilizumab triple doses (n = 3) | Bevacizumab alone (n = 25) | Tocilizumab plus Bevacizumab (n = 21) |
|---|---|---|---|---|---|---|---|---|
| Duration of ICU stay, mean ± SD - day | 6.54 ± 5.49 | 5.71 ± 4.93 | 7.89 ± 6.08 | 6.10 ± 5.54 | 7.93 ± 5.89 | 7.00 ± 5.57 | 4.57 ± 3.60 | 7.43 ± 5.40 |
| Discharged - no. (%) | 122 (61) | - | - | 73 (72) | 10 (21) | 2 (67) | 23 (92) | 14 (67) |
| Expired - no. (%) | 77 (39) | - | - | 29 (28) | 38 (79) | 1 (33) | 2 (8) | 7 (33) |